VWF is a multimeric high molecular weight (HPM) glycoprotein involved in primary hemostasis.
VWF protects FVIII from degradation and transports it to plasma, and mediates platelet activation by binding to their membrane receptors GPIb and GPIIb / IIIa.
A quantitative or qualitative defect of VWF causes hemorrhagic pathologies which can be acquired or hereditary. VWF assay is needed to determine the type of disease.
- Reflects the physiological activity of VWF in plasma and concentrates.
- Better distinguish types 2A and 2B from type 1.
- Marker of response to DDAVP.
- Detects high concentrations of VWF from HPM in PTT (Thrombotic Thrombocytopenic Purpura).
- Detects low concentrations of low molecular weight VWF in TE (Essential Thrombocythemia).
- Used to identify samples with a proven deficit of VWF multimers.
- Stability 6 months after opening.
- Reaction time 60 minutes.
- Sensitivity : 0 - 1.5 IU / mL
- Detection limit : 0.01 IU / mL
- Better reproducibility.
- Better sensitivity.
- Better correlation with high molecular weight (HPM) forms of VWF.
- Better sensitivity in detecting low amounts of VWF in severe type 1 deficiency.
- 12 breakable ELISA strips (12 x 8 wells)
- 2 adhesives for ELISA plate
- 1 vial x anti-VWF-POX conjugate antibody (0.3 mL)
- 1 vial x TMB substrate (12 mL)
- 1 vial x wash buffer concentrate (80 mL)
- 1 vial x incubation buffer (90 mL)
- 5 vials x freeze-dried calibrators
- 1 vial x lyophilized low control plasma
- 1 vial x lyophilized high control plasma
